These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27394925)

  • 1. Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Gezer M; Taş A; Eyileten T; Guler AK; Aydin İ; Oguz Y; Tarim K; Covic A; Yilmaz MI
    Eur J Intern Med; 2016 Sep; 33():81-7. PubMed ID: 27394925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.
    Solak Y; Yilmaz MI; Siriopol D; Saglam M; Unal HU; Yaman H; Gok M; Cetinkaya H; Gaipov A; Eyileten T; Sari S; Yildirim AO; Tonbul HZ; Turk S; Covic A; Kanbay M
    Int Urol Nephrol; 2015 Dec; 47(12):1993-2001. PubMed ID: 26498629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Plasma Whole Blood Viscosity and Cardiovascular Events in Patients With Chronic Kidney Disease.
    Celik T; Yilmaz MI; Balta S; Ozturk C; Unal HU; Aparci M; Karaman M; Demir M; Yildirim AO; Saglam M; Kilic S; Eyileten T; Aydin İ; Iyisoy A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):663-670. PubMed ID: 26907084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between endostatin and kidney disease and mortality in patients with type 2 diabetes.
    Carlsson AC; Östgren CJ; Länne T; Larsson A; Nystrom FH; Ärnlöv J
    Diabetes Metab; 2016 Nov; 42(5):351-357. PubMed ID: 27080454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Cardiovascular Events on End-Stage Renal Disease and Mortality in Patients With Chronic Kidney Disease Before Dialysis.
    Kuwahara M; Takehara E; Sasaki Y; Azetsu H; Kusaka K; Shikuma S; Akita W
    Ther Apher Dial; 2016 Feb; 20(1):12-9. PubMed ID: 26679409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of BP with Death, Cardiovascular Events, and Progression to Chronic Dialysis in Patients with Advanced Kidney Disease.
    Palit S; Chonchol M; Cheung AK; Kaufman J; Smits G; Kendrick J
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):934-40. PubMed ID: 25979975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival.
    Gungor O; Unal HU; Guclu A; Gezer M; Eyileten T; Guzel FB; Altunoren O; Erken E; Oguz Y; Kocyigit I; Yilmaz MI
    PLoS One; 2017; 12(6):e0178939. PubMed ID: 28614418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease.
    Yilmaz MI; Siriopol D; Saglam M; Kurt YG; Unal HU; Eyileten T; Gok M; Cetinkaya H; Oguz Y; Sari S; Vural A; Mititiuc I; Covic A; Kanbay M
    Kidney Int; 2014 Dec; 86(6):1213-20. PubMed ID: 24988065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events.
    Yilmaz MI; Siriopol D; Saglam M; Unal HU; Karaman M; Gezer M; Kilinc A; Eyileten T; Guler AK; Aydin İ; Vural A; Oguz Y; Covic A; Ortiz A; Kanbay M
    Calcif Tissue Int; 2016 Aug; 99(2):121-30. PubMed ID: 27016924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts.
    Ruge T; Carlsson AC; Larsson TE; Carrero JJ; Larsson A; Lind L; Ärnlöv J
    Am J Nephrol; 2014; 40(5):417-24. PubMed ID: 25401956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register.
    Afghahi H; Svensson MK; Pirouzifard M; Eliasson B; Svensson AM
    Diabetologia; 2015 Jun; 58(6):1203-11. PubMed ID: 25773403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma levels of endostatin are associated with chronic kidney disease.
    Chen J; Hamm LL; Kleinpeter MA; Husserl F; Khan IE; Chen CS; Liu Y; Mills KT; He C; Rifai N; Simon EE; He J
    Am J Nephrol; 2012; 35(4):335-40. PubMed ID: 22456114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BMI on cardiovascular events, renal function, and coronary artery calcification.
    Russo D; Morrone LF; Errichiello C; De Gregorio MG; Imbriaco M; Battaglia Y; Russo L; Andreucci M; Di Iorio BR
    Blood Purif; 2014; 38(1):1-6. PubMed ID: 25196674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease.
    Wątorek E; Paprocka M; Duś D; Kopeć W; Klinger M
    Pol Arch Med Wewn; 2011 Sep; 121(9):296-301. PubMed ID: 21909059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
    Kanbay M; Yilmaz MI; Apetrii M; Saglam M; Yaman H; Unal HU; Gok M; Caglar K; Oguz Y; Yenicesu M; Cetinkaya H; Eyileten T; Acikel C; Vural A; Covic A
    Am J Nephrol; 2012; 36(3):228-37. PubMed ID: 22948239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Shah R; Matthews GJ; Shah RY; McLaughlin C; Chen J; Wolman M; Master SR; Chai B; Xie D; Rader DJ; Raj DS; Mehta NN; Budoff M; Fischer MJ; Go AS; Townsend RR; He J; Kusek JW; Feldman HI; Foulkes AS; Reilly MP;
    Am J Kidney Dis; 2015 Aug; 66(2):266-73. PubMed ID: 25795074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study.
    Ruge T; Carlsson AC; Kjøller E; Hilden J; Kolmos HJ; Sajadieh A; Kastrup J; Jensen GB; Larsson A; Nowak C; Jakobsen JC; Winkel P; Gluud C; Ärnlöv J
    Atherosclerosis; 2019 May; 284():202-208. PubMed ID: 30959314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endostatin Is an Independent Risk Factor of Graft Loss after Kidney Transplant.
    Chu C; Hasan AA; Gaballa MMS; Zeng S; Xiong Y; Elitok S; Krämer BK; Hocher B
    Am J Nephrol; 2020; 51(5):373-380. PubMed ID: 32320989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.